-
1دورية أكاديمية
المؤلفون: Kvorning Ternov K; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark klara.kvorning.ternov@regionh.dk., Sønksen J; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Fode M; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Lindberg H; Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark., Kistorp CM; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Bisbjerg R; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Palapattu G; Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA., Østergren PB; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark.
المصدر: BMJ open [BMJ Open] 2019 Sep 11; Vol. 9 (9), pp. e030218. Date of Electronic Publication: 2019 Sep 11.
نوع المنشور: Clinical Trial Protocol; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
مواضيع طبية MeSH: Androgen Antagonists/*therapeutic use , Androstenes/*therapeutic use , Phenylthiohydantoin/*analogs & derivatives , Prednisolone/*therapeutic use , Prostatic Neoplasms, Castration-Resistant/*drug therapy, Androgen Antagonists/adverse effects ; Androstenes/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzamides ; Blood Glucose/metabolism ; Clinical Trials, Phase III as Topic ; Denmark ; Fatigue/chemically induced ; Humans ; Male ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Nitriles ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/therapeutic use ; Prednisolone/adverse effects ; Prostatic Neoplasms, Castration-Resistant/mortality ; Quality of Life ; Randomized Controlled Trials as Topic ; Risk Assessment ; Survival Analysis ; Treatment Outcome
-
2دورية أكاديمية
المؤلفون: Newton RU; Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia.; School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, Queensland, Australia.; School of Medical and Health Science, Edith Cowan University, Perth, Western Australia, Australia., Kenfield SA; Department of Urology, University of California San Francisco, San Francisco, California, USA., Hart NH; Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia.; School of Medical and Health Science, Edith Cowan University, Perth, Western Australia, Australia.; Institute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia., Chan JM; Department of Urology, University of California San Francisco, San Francisco, California, USA.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA., Courneya KS; Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia.; Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada., Catto J; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK., Finn SP; School of Medicine, Trinity College Dublin, Dublin, Ireland., Greenwood R; University Hospitals Bristol, NHS Foundation Trust, Bristol, UK., Hughes DC; Institute for Health Promotion Research, University of Texas Health, San Antonio, Texas, UK., Mucci L; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA., Plymate SR; Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, Washington, USA., Praet SFE; Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, Washington, USA.; University of Canberra Research Institute for Sport and Exercise, University of Canberra, Canberra, Australia., Guinan EM; Cancer Trials Ireland, Dublin, Ireland., Van Blarigan EL; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA., Casey O; Cancer Trials Ireland, Dublin, Ireland., Buzza M; Movember Foundation, Melbourne, Victoria, Australia., Gledhill S; Movember Foundation, Melbourne, Victoria, Australia., Zhang L; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Galvão DA; Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia.; School of Medical and Health Science, Edith Cowan University, Perth, Western Australia, Australia., Ryan CJ; Department of Urology, University of California San Francisco, San Francisco, California, USA.; Department of Medicine, University of California San Francisco, San Francisco, California, USA.; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Saad F; Department of Urology, Centre Hospitalier de L'Universite de Montreal, Montreal, Quebec, Canada.
المصدر: BMJ open [BMJ Open] 2018 May 14; Vol. 8 (5), pp. e022899. Date of Electronic Publication: 2018 May 14.
نوع المنشور: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
مواضيع طبية MeSH: Quality of Life*, Androgen Antagonists/*therapeutic use , Exercise Therapy/*methods , Prostatic Neoplasms, Castration-Resistant/*mortality , Prostatic Neoplasms, Castration-Resistant/*therapy, Androstenes/therapeutic use ; Benzamides ; Clinical Trials, Phase III as Topic ; Disease Progression ; Humans ; Male ; Multicenter Studies as Topic ; Nitriles ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Randomized Controlled Trials as Topic ; Receptors, Androgen/drug effects ; United States/epidemiology
-
3
المؤلفون: Gaku Arai, Hisashi Matsushima, Hiroji Uemura, Vince Grillo, Takefumi Satoh, Dianne Athene Ledesma, Akira Yokomizo, Yirong Chen, Shikha Satendra Singh, Kazuki Kobayashi
المصدر: BMJ Open, Vol 11, Iss 8 (2021)
BMJ Openمصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Side effect, medicine.drug_class, medicine.medical_treatment, Discrete choice experiment, Antiandrogen, Unmet needs, Prostate cancer, Japan, Prostate, Internal medicine, Humans, Medicine, urological tumours, Chemotherapy, business.industry, Androgen Antagonists, Bayes Theorem, General Medicine, medicine.disease, Prostatic Neoplasms, Castration-Resistant, Cross-Sectional Studies, medicine.anatomical_structure, Oncology, adult oncology, Observational study, business, prostate disease
-
4
المؤلفون: Xianzhi Zhao, Tao Wang, Yusheng Ye, Jing Li, Xu Gao, Huojun Zhang
المصدر: BMJ Open. 12:e051371
مصطلحات موضوعية: Male, China, Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Androgens, Humans, Prostatic Neoplasms, Androgen Antagonists, Gallium Radioisotopes, Prospective Studies, General Medicine, Radiosurgery, Randomized Controlled Trials as Topic
-
5
المؤلفون: Jens Sønksen, Peter Busch Østergren, Mikkel Fode, Caroline Kistorp, Ganesh S. Palapattu, Klara Kvorning Ternov, H. Lindberg, Rasmus Bisbjerg
المصدر: BMJ Open
Ternov, K K, Sønksen, J, Fode, M, Lindberg, H, Kistorp, C M, Bisbjerg, R, Palapattu, G & Østergren, P B 2019, ' Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT) : A randomised trial protocol ', BMJ Open, vol. 9, no. 9, e030218 . https://doi.org/10.1136/bmjopen-2019-030218مصطلحات موضوعية: Blood Glucose, Male, Denmark, law.invention, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Protocol, 030212 general & internal medicine, Abiraterone, Fatigue, Randomized Controlled Trials as Topic, Randomised controlled trial, Abiraterone acetate, General Medicine, prostate cancer, castration resistant, Prostatic Neoplasms, Castration-Resistant, side effects, Treatment Outcome, 030220 oncology & carcinogenesis, Benzamides, Androstenes, medicine.medical_specialty, Prednisolone, Urology, Risk Assessment, 03 medical and health sciences, Internal medicine, Nitriles, Phenylthiohydantoin, medicine, Enzalutamide, Humans, Neoplasm Invasiveness, Hormone therapy, Neoplasm Staging, business.industry, Androgen Antagonists, medicine.disease, Survival Analysis, Clinical trial, chemistry, Clinical Trials, Phase III as Topic, quality of life, prostate neoplasm, Adverse events, Metabolic changes, Prostate neoplasm, business
وصف الملف: application/pdf
-
6
المؤلفون: Charles J. Ryan, James W.F. Catto, Lorelei A. Mucci, Mark Buzza, Orla Casey, Emer Guinan, Robert U. Newton, Kerry S. Courneya, June M. Chan, Stephen P. Finn, Rosemary Greenwood, Sam Gledhill, Stephen R. Plymate, Daniel A. Galvão, Stephan Praet, Fred Saad, Stacey A. Kenfield, Nicolas H. Hart, Daniel C. Hughes, Li Zhang, Erin L. Van Blarigan
المصدر: BMJ Open
BMJ open, vol 8, iss 5مصطلحات موضوعية: Oncology, Male, Aging, physical activity, Castration-Resistant, law.invention, Androgen, Androgen deprivation therapy, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Quality of life, Randomized controlled trial, law, Receptors, Clinical endpoint, Protocol, Medicine, Multicenter Studies as Topic, 030212 general & internal medicine, Cancer, Randomized Controlled Trials as Topic, immune function, Prostate Cancer, Pain Research, General Medicine, Exercise Therapy, Phase III as Topic, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Benzamides, Public Health and Health Services, Androstenes, Chronic Pain, Urologic Diseases, medicine.medical_specialty, Clinical Trials and Supportive Activities, Clinical Sciences, Physical exercise, 03 medical and health sciences, disease progression, Clinical Research, Internal medicine, Nitriles, Phenylthiohydantoin, Enzalutamide, Humans, Clinical Trials, Other Medical and Health Sciences, business.industry, Prostatic Neoplasms, Evaluation of treatments and therapeutic interventions, tumour biology, Androgen Antagonists, medicine.disease, United States, Good Health and Well Being, chemistry, Clinical Trials, Phase III as Topic, inflammation, Quality of Life, business, Progressive disease
وصف الملف: application/pdf
إعادة تعيين المنقحات
عرض المنقحات (%%عد%%)
Full Text Finder